Eli Lilly & Co. to Acquire Morphic Holding Inc. in a USD 3.2 Billion Deal
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced...
Roche’s Susvimo Implant Cleared for Relaunch in US After Voluntary Recall
Roche (SWX: RO), the Swiss pharmaceutical giant, has announced the conclusion of the voluntary recall...
Boston Scientific’s FARAPULSE Pulse Field Ablation System Earns NMPA Approval
Boston Scientific Corporation (NYSE: BSX), a leading medical device company in the U.S., has announced...
Ascentage Pharma’s Olverembatinib Receives Marketing Approval from Macau SAR for CML Treatment
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has...
Keymed Biosciences Strikes Licensing Deal with Belenos Biosciences for Global BsAb Rights
Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has entered into a...
Quantum Hi-Tech Partners with East China Normal University to Establish Advanced Drug Research Lab
Quantum Hi-Tech (China) Biotechnology Co., Ltd, known as ChemPartner (SHE: 300149), has entered into a...
China Isotope & Radiation Corporation to Establish Cancer Treatment Center in Nigeria
China Isotope & Radiation Corporation (CIRC; HKG: 1763), a leading provider of medical equipment and...
Shanghai Fosun Pharmaceutical Gets NMPA Green Light for FH-2001 and Serplulimab Combo Clinical Trial
Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196), a prominent pharmaceutical company in...
CSPC Pharmaceutical’s SYS6023 Receives FDA Approval for Clinical Study in Advanced Solid Tumors
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...
Allist Pharmaceuticals Receives NMPA Approval for Phase III Trial of Furmonertinib in EGFR Mutated NSCLC
Allist Pharmaceuticals Co., Ltd, a Shanghai-based biopharmaceutical company, has announced that it has received approval...
China’s State Council Reportedly Approves Plan to Support Full Industry Chain of Innovative Drug Development
A State Council executive meeting, chaired by Chinese Premier Li Qiang, reportedly approved an “Implementation...
AusperBio’s AHB-137 Antiviral Candidate on Path to Breakthrough Designation for Chronic Hepatitis B in China
AusperBio, a sino-American developer specializing in liver therapies, has announced that its drug candidate AHB-137...
Yantai Dongcheng Pharmaceutical Gets NMPA Approval for ⁹⁹ᵐTc Tetrofosmin Imaging Agent
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a pharmaceutical company based in China, has...
Shenzhen Salubris Pharmaceuticals’ Fotagliptin Receives NMPA Approval for Type 2 Diabetes Treatment
Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a pharmaceutical company based in China, has announced...
Roche’s Alecensa Secures NMPA Approval as Adjuvant Therapy for Early-Stage NSCLC
Roche (SWX: RO), the Swiss pharmaceutical giant, has announced that it has received an additional...
Immorna Earns FDA Approval for Phase I/II Clinical Trial of Self-Replicating RNA Cancer Therapy
Immorna (Hangzhou) Biotechnology, a biotech company specializing in mRNA-based vaccines and located in Hangzhou, has...
Novo Nordisk’s Esperoct Receives NMPA Approval, First Long-Acting Factor VIII for Hemophilia A in China
The National Medical Products Administration (NMPA) has granted approval to Novo Nordisk (NYSE: NVO), a...
Xinzeyuan Medical Technology Secures Over RMB 100 Million in Series B Financing
Xinzeyuan Medical Technology Co., Ltd, a Hangzhou-based micro invasive medical device supply chain platform, has...
Innovent Biologics and IASO Biotherapeutics Amend Partnership, Focusing on CAR-T Therapy Fucaso
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced a...
PharmaEssentia’s Besremi Receives Approval for Polycythemia Vera Treatment in China
PharmaEssentia Corporation (TPE: 6446, FRA: 8Z1), a biopharmaceutical company based in Taiwan, has announced that...